Journal of clinical lipidology · 2026
Plasma-based low-grade inflammation and endothelial dysfunction explain a small but significant proportion of the association between the n-3 polyunsaturated fatty acids and cardiovascular diseases: The Maastricht Study.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tore Elena C, Briones Ana M, Bruno Rosa Maria, Dalli Jesmond, Eussen Simone J P M, Schalkwijk Casper G, van Greevenbroek Marleen M J
Аннотация
BACKGROUND: n-3 polyunsaturated fatty acids (PUFAs) are linked to lower cardiovascular disease (CVD) risk, potentially via reduced low-grade inflammation (LGI).
OBJECTIVE: To examine whether LGI mediates the association of n-3 PUFAs with (pre)clinical CVD, and whether LGI and endothelial dysfunction (ED) mediate the associations with clinical CVD.
METHODS: Cross-sectional data from The Maastricht Study were analyzed. Fasted n-3 PUFAs were measured with 1H nuclear magnetic resonance (NMR; n = 3193, 50.8% men, 60 ± 8 years; EDTA plasma) and gas chromatography (GC; n = 1032, 49.6% men, 60 ± 8 years; serum). LGI was defined as the z-score of 6 plasma biomarkers. Preclinical markers of CVD comprised: ED, ankle-brachial index, carotid intima-media thickness, and carotid-femoral pulse wave velocity. CVD was self-reported as coronary heart disease, cerebrovascular disease, or peripheral artery disease. Mediations with n-3 PUFAs (exposures), LGI (mediator), and (pre)clinical CVD (outcomes), and sequential mediations with LGI and ED (mediators) and CVD (outcome) were performed.
RESULTS: A total of 522 participants reported CVD. In the NMR subset, n-3 PUFAs were inversely associated with CVD and ED. n-3 PUFAs were inversely associated with LGI (β: -0.09 [-0.12, -0.05]), while LGI was positively associated with ED (β: 0.58 [0.55, 0.61]) and CVD (OR: 1.15 [1.03, 1.28]). LGI mediated the associations with CVD (<5%) and ED (54.4%). LGI and ED mediated small but significant proportions of the associations with CVD (<5%). Similar, although nonsignificant, results were observed in the GC subset.
CONCLUSION: Biomarker-based LGI mediated substantial parts of the associations with ED, while together they mediated a small proportion of the associations between n-3 PUFAs and CVD. Further studies are warranted to identify the metabolic pathways via which n-3 PUFAs influence CVD, and the role of LGI in early stages of CVD.
OBJECTIVE: To examine whether LGI mediates the association of n-3 PUFAs with (pre)clinical CVD, and whether LGI and endothelial dysfunction (ED) mediate the associations with clinical CVD.
METHODS: Cross-sectional data from The Maastricht Study were analyzed. Fasted n-3 PUFAs were measured with 1H nuclear magnetic resonance (NMR; n = 3193, 50.8% men, 60 ± 8 years; EDTA plasma) and gas chromatography (GC; n = 1032, 49.6% men, 60 ± 8 years; serum). LGI was defined as the z-score of 6 plasma biomarkers. Preclinical markers of CVD comprised: ED, ankle-brachial index, carotid intima-media thickness, and carotid-femoral pulse wave velocity. CVD was self-reported as coronary heart disease, cerebrovascular disease, or peripheral artery disease. Mediations with n-3 PUFAs (exposures), LGI (mediator), and (pre)clinical CVD (outcomes), and sequential mediations with LGI and ED (mediators) and CVD (outcome) were performed.
RESULTS: A total of 522 participants reported CVD. In the NMR subset, n-3 PUFAs were inversely associated with CVD and ED. n-3 PUFAs were inversely associated with LGI (β: -0.09 [-0.12, -0.05]), while LGI was positively associated with ED (β: 0.58 [0.55, 0.61]) and CVD (OR: 1.15 [1.03, 1.28]). LGI mediated the associations with CVD (<5%) and ED (54.4%). LGI and ED mediated small but significant proportions of the associations with CVD (<5%). Similar, although nonsignificant, results were observed in the GC subset.
CONCLUSION: Biomarker-based LGI mediated substantial parts of the associations with ED, while together they mediated a small proportion of the associations between n-3 PUFAs and CVD. Further studies are warranted to identify the metabolic pathways via which n-3 PUFAs influence CVD, and the role of LGI in early stages of CVD.